• 1. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 2. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 3. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 4. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 5. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoyl derivatives

Recent Advances in the Study of 2-Butoxy-3-methoxybenzaldehyde (CAS: 65712-73-4) in Chemical Biology and Pharmaceutical Research

The compound 2-Butoxy-3-methoxybenzaldehyde (CAS: 65712-73-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, biological activity, and potential applications in drug development. The compound's distinct chemical structure, featuring both butoxy and methoxy substituents on the benzaldehyde core, makes it a promising candidate for further investigation in medicinal chemistry.

Recent studies have highlighted the synthetic versatility of 2-Butoxy-3-methoxybenzaldehyde, with several research groups reporting novel synthetic routes to improve yield and purity. A 2023 study published in the Journal of Medicinal Chemistry demonstrated an optimized two-step synthesis starting from 3-methoxybenzaldehyde, achieving a 78% overall yield with high purity (>98%). This advancement is particularly significant for scaling up production for preclinical studies. Additionally, the compound's stability under various physiological conditions has been characterized, showing promising results for its potential as a drug precursor.

In terms of biological activity, preliminary screening has revealed interesting pharmacological properties of 2-Butoxy-3-methoxybenzaldehyde. Research conducted at the University of California, San Francisco (2024) identified moderate inhibitory activity against several kinase targets, particularly showing promise in the low micromolar range against JAK2 and FLT3 kinases. These findings suggest potential applications in oncology, particularly for hematological malignancies where these kinase pathways play crucial roles. The compound's ability to penetrate cell membranes effectively, as demonstrated in cellular uptake studies, further supports its potential as a lead compound for drug development.

The mechanism of action of 2-Butoxy-3-methoxybenzaldehyde is currently under investigation. Molecular docking studies published in Bioorganic & Medicinal Chemistry Letters (2024) suggest that the compound may interact with the ATP-binding sites of target kinases through hydrogen bonding with the aldehyde group and hydrophobic interactions with the butoxy side chain. These computational predictions are being validated through ongoing crystallography studies, which aim to provide atomic-level insights into the compound's binding mode.

From a pharmaceutical development perspective, the pharmacokinetic profile of 2-Butoxy-3-methoxybenzaldehyde shows both promising and challenging aspects. While the compound demonstrates good oral bioavailability in rodent models (approximately 65%), its metabolic stability in human liver microsomes requires optimization, with a half-life of just 12 minutes observed in recent in vitro studies. Several research groups are currently working on structural modifications to address this limitation while maintaining the compound's biological activity.

Looking forward, the potential applications of 2-Butoxy-3-methoxybenzaldehyde extend beyond its current investigation as a kinase inhibitor. Its unique chemical structure makes it a valuable building block for the synthesis of more complex molecules, and several research teams are exploring its use in fragment-based drug discovery. Furthermore, its potential as an anti-inflammatory agent is being investigated, with preliminary data showing inhibition of NF-κB signaling in macrophage cell lines.

In conclusion, 2-Butoxy-3-methoxybenzaldehyde (CAS: 65712-73-4) represents an intriguing compound with multiple potential applications in pharmaceutical research. While challenges remain in optimizing its pharmacokinetic properties, the current body of research suggests it could serve as either a valuable lead compound or a versatile chemical building block. Continued investigation into its mechanism of action and structure-activity relationships will be crucial for fully realizing its therapeutic potential.

• 100256-89-1(3-Ethoxy-2-propoxybenzaldehyde)
• 116827-92-0(BENZALDEHYDE, 2-HYDROXY-3-(OCTYLOXY)-)
• 849238-16-0(17H-DIBENZO[B,K][1,4,7,10,13]PENTAOXACYCLOOCTADECIN-4-CARBOXALDEHYDE, 6,7,9,10,18,19,20,21-OCTAHYDRO-)
• 52049-39-5(Benzaldehyde, 3-(hexadecyloxy)-2-hydroxy-)
• 1154340-59-6(2-(Cyclopropylmethoxy)-3-methoxybenzaldehyde)
• 849238-20-6(3-(Octyloxy)-2-(2-{2-[2-(octyloxy)phenoxy]ethoxy}ethoxy)benzaldehyde)
• 849238-24-0(17H-DIBENZO[B,K][1,4,7,10,13]PENTAOXACYCLOOCTADECIN-1-CARBOXALDEHYDE, 6,7,9,10,18,19,20,21-OCTAHYDRO-)
• 879014-56-9(1,4-BENZENEDICARBOXALDEHYDE, 2,3-BIS(OCTYLOXY)-)
• 41828-10-8(3-methoxy-2-propoxybenzaldehyde)
• 879014-54-7(1,4-BENZENEDICARBOXALDEHYDE, 2,3-BIS(PENTYLOXY)-)